John Libbey Eurotext

Annales de Biologie Clinique

Apport du dosage de l’hepcidine pour le diagnostic et le suivi de pathologies associées à une anémie Volume 75, numéro 1, Janvier-Février 2017

  • [1] Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721-1741.
  • [2] Brasse-Lagnel C., Karim Z., Letteron P., Bekri S., Bado A., Beaumont C. Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. Gastroenterology. 2011;140:1261-71 e1.
  • [3] Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425-4433.
  • [4] Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38:531-539.
  • [5] Guillem F., Lawson S., Kannengiesser C., Westerman M., Beaumont C., Grandchamp B. Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency. Blood. 2008;112:2089-2091.
  • [6] Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-1276.
  • [7] Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
  • [8] Papanikolaou G., Tzilianos M., Christakis J.I., Bogdanos D., Tsimirika K., MacFarlane J. Hepcidin in iron overload disorders. Blood. 2005;105:4103-4105.
  • [9] Tanno T., Bhanu N.V., Oneal P.A., Goh S.H., Staker P., Lee Y.T. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096-1101.
  • [10] Tanno T., Porayette P., Sripichai O., Noh S.J., Byrnes C., Bhupatiraju A. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009;114:181-186.
  • [11] Kautz L., Jung G., Valore E.V., Rivella S., Nemeth E., Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678-684.
  • [12] Keel S.B., Doty R., Liu L., Nemeth E., Cherian S., Ganz T. Evidence that the expression of transferrin receptor 1 on erythroid marrow cells mediates hepcidin suppression in the liver. Exp Hematol. 2015;43:469-478.
  • [13] Nai A., Lidonnici M.R., Rausa M., Mandelli G., Pagani A., Silvestri L. The second transferrin receptor regulates red blood cell production in mice. Blood. 2015;125:1170-1179.
  • [14] Ribeil J.A., Arlet J.B., Dussiot M., Moura I.C., Courtois G., Hermine O. Ineffective erythropoiesis in beta -thalassemia. ScientificWorldJournal. 2013;2013:394295.
  • [15] Gardenghi S., Grady R.W., Rivella S. Anemia, ineffective erythropoiesis, and hepcidin : interacting factors in abnormal iron metabolism leading to iron overload in beta-thalassemia. Hematol Oncol Clin North Am. 2010;24:1089-1107.
  • [16] Finkenstedt A., Bianchi P., Theurl I., Vogel W., Witcher D.R., Wroblewski V.J. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol. 2009;144:789-793.
  • [17] Cuijpers M.L., Raymakers R.A., Mackenzie M.A., de Witte T.J., Swinkels D.W. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome. Br J Haematol. 2010;149:322-333.
  • [18] Delbini P., Vaja V., Graziadei G., Duca L., Nava I., Refaldi C. Genetic variability of TMPRSS6 and its association with iron deficiency anaemia. Br J Haematol. 2010;151:281-284.
  • [19] Hershko C., Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood. 2014;123:326-333.
  • [20] Finberg K.E., Heeney M.M., Campagna D.R., Aydinok Y., Pearson H.A., Hartman K.R. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40:569-571.
  • [21] Donker A.E., Raymakers R.A., Vlasveld L.T., van Barneveld T., Terink R., Dors N. Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis. Blood. 2014;123:3873-86. quiz 4005
  • [22] Guillem F., Grandchamp B. Mutations du gène TMPRSS6 dans les anémies de type IRIDA et effet des variants fréquents sur les paramètres hématologiques. Hématologie. 201117.
  • [23] Finberg K.E. Iron-refractory iron deficiency anemia. Semin Hematol. 2009;46:378-386.
  • [24] Silvestri L., Guillem F., Pagani A., Nai A., Oudin C., Silva M. Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. Blood. 2009;113:5605-5608.
  • [25] De Falco L., Silvestri L., Kannengiesser C., Moran E., Oudin C., Rausa M. Functional and clinical impact of novel TMPRSS6 variants in iron-refractory iron-deficiency anemia patients and genotype-phenotype studies. Hum Mutat. 2014;35:1321-1329.
  • [26] Silvestri L., Rausa M., Pagani A., Nai A., Camaschella C. How to assess causality of TMPRSS6 mutations ? Hum Mutat. 2013;34:1043-1045.
  • [27] Bregman D.B., Morris D., Koch T.A., He A., Goodnough L.T. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol. 2013;88:97-101.
  • [28] Melis M.A., Cau M., Congiu R., Sole G., Barella S., Cao A. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica. 2008;93:1473-1479.
  • [29] Ludwig H., Van Belle S., Barrett-Lee P., Birgegard G., Bokemeyer C., Gascon P. The European Cancer Anaemia Survey (ECAS) : a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293-2306.
  • [30] Dicato M., Plawny L., Diederich M. Anemia in cancer. Ann Oncol. 2010;21:vii167-vii172. Suppl. 7
  • [31] Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. 2002;16:87-96.
  • [32] Schwartz R.N. Anemia in patients with cancer : incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm. 2007;64:S5-13. 3 Suppl 2quiz S28-30
  • [33] Auclerc G., Meric J.B., Pommeyrol A., Rixe O., Khayat D. Anemia in cancer patients before treatment. Bull Cancer. 2003;90:S128-S132. Suppl.
  • [34] Durigova A., Jacot W., Pouderoux S., Roques S., Montels F., Lamy P.J. Iron metabolism in breast cancer : knowledge and future. Ann Biol Clin (Paris). 2012;70:387-396.
  • [35] Vincent J.L., Baron J.F., Reinhart K., Gattinoni L., Thijs L., Webb A. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288:1499-1507.
  • [36] Walsh T.S., Lee R.J., Maciver C.R., Garrioch M., Mackirdy F., Binning A.R. Anemia during and at discharge from intensive care : the impact of restrictive blood transfusion practice. Intensive Care Med. 2006;32:100-109.
  • [37] Bateman A.P., McArdle F., Walsh T.S. Time course of anemia during six months follow up following intensive care discharge and factors associated with impaired recovery of erythropoiesis. Crit Care Med. 2009;37:1906-1912.
  • [38] Lasocki S., Chudeau N., Papet T., Tartiere D., Roquilly A., Carlier L. Prevalence of iron deficiency on ICU discharge and its relation with fatigue : a multicenter prospective study. Crit Care. 2014;18:542.
  • [39] Heming N., Letteron P., Driss F., Millot S., El Benna J., Tourret J. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia. Crit Care Med. 2012;40:2141-2148.
  • [40] Cheng P.P., Jiao X.Y., Wang X.H., Lin J.H., Cai Y.M. Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia. Clin Exp Med. 2011;11:33-42.
  • [41] Lasocki S., Baron G., Driss F., Westerman M., Puy H., Boutron I. Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Med. 2010;36:1044-1048.
  • [42] Lasocki S., Longrois D., Montravers P., Beaumont C. Hepcidin and anemia of the critically ill patient : bench to bedside. Anesthesiology. 2011;114:688-694.
  • [43] Macdougall I.C. Anaemia and chronic renal failure. Medicine. 2015;39:425-428.
  • [44] Babitt J.L., Lin H.Y. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631-1634.
  • [45] Fishbane S., Pollack S., Feldman H.I., Joffe M.M. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol. 2009;4:57-61.
  • [46] Zaritsky J., Young B., Wang H.J., Westerman M., Olbina G., Nemeth E. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1051-1056.
  • [47] Mercadal L., Metzger M., Haymann J.P., Thervet E., Boffa J.J., Flamant M. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One. 2014;9:e99781.
  • [48] Drueke T.B., Parfrey P.S. Summary of the KDIGO guideline on anemia and comment : reading between the (guide)line(s). Kidney Int. 2012;82:952-960.
  • [49] Peters H.P., Rumjon A., Bansal S.S., Laarakkers C.M., van den Brand J.A., Sarafidis P. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrol Dial Transplant. 2012;27:3923-3929.